National Planning Corporation’s PDL BioPharma, Inc. PDLI Stock Holding History

National Planning Corporation’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-8,962	Closed	-$66K	–	2718
2014 Q4	$66K	Sell	8,962 -8,000	-47%	-$63.3K	﹤0.01%	1122
2014 Q3	$129K	Buy	+16,962	New	+$157K	0.01%	709

Other funds holding PDLI

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

National Planning Corporation's PDLI Position: Q1 2015 in Review

National Planning Corporation sold out of PDL BioPharma, Inc. (PDLI) in Q1 2015, closing a stake of 8,962 shares — an estimated $66K sold.

National Planning Corporation first reported a position in PDLI in Q3 2014 and held it in 2 quarters. The position peaked at $129K in Q3 2014. 215 funds tracked by Wall St. Rank hold PDLI as of Q1 2015.

National Planning Corporation reported no remaining PDL BioPharma, Inc. position as of Q1 2015 after selling out during the quarter.
National Planning Corporation sold 8,962 PDL BioPharma, Inc. shares in Q1 2015, an estimated $66K.
National Planning Corporation first reported a position in PDL BioPharma, Inc. in Q3 2014 and held it in 2 quarters.
National Planning Corporation's PDL BioPharma, Inc. position peaked at $129K in Q3 2014.
215 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2015.

Based on National Planning Corporation's 13F filing for Q1 2015, filed 12 May 2015.